Vera Therapeutics (VERA) Competitors $19.79 +0.07 (+0.35%) Closing price 04:00 PM EasternExtended Trading$19.80 +0.01 (+0.03%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. CRSP, LNTH, ADMA, MRUS, ABVX, TGTX, TLX, RNA, CYTK, and PCVXShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include CRISPR Therapeutics (CRSP), Lantheus (LNTH), ADMA Biologics (ADMA), Merus (MRUS), Abivax (ABVX), TG Therapeutics (TGTX), Telix Pharmaceuticals (TLX), Avidity Biosciences (RNA), Cytokinetics (CYTK), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors CRISPR Therapeutics Lantheus ADMA Biologics Merus Abivax TG Therapeutics Telix Pharmaceuticals Avidity Biosciences Cytokinetics Vaxcyte Vera Therapeutics (NASDAQ:VERA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Do institutionals & insiders have more ownership in VERA or CRSP? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is VERA or CRSP more profitable? Vera Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -46.70% -39.46% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Do analysts prefer VERA or CRSP? Vera Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 218.34%. CRISPR Therapeutics has a consensus target price of $71.60, indicating a potential upside of 30.18%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vera Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, VERA or CRSP? Vera Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Does the media favor VERA or CRSP? In the previous week, CRISPR Therapeutics had 17 more articles in the media than Vera Therapeutics. MarketBeat recorded 40 mentions for CRISPR Therapeutics and 23 mentions for Vera Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.58 beat Vera Therapeutics' score of 0.10 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 8 Very Positive mention(s) 10 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, VERA or CRSP? Vera Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$152.15M-$3.58-5.53CRISPR Therapeutics$37.31M134.07-$366.25M-$5.43-10.13 SummaryVera Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.26B$2.98B$5.45B$9.68BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-5.5317.9230.0525.00Price / SalesN/A174.46378.2478.85Price / CashN/A41.8335.9458.58Price / Book2.707.278.145.68Net Income-$152.15M-$54.43M$3.25B$265.58M7 Day Performance-5.54%0.00%1.16%2.51%1 Month Performance-13.96%5.14%2.82%1.88%1 Year Performance-44.80%10.25%28.41%24.02% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics3.0922 of 5 stars$19.79+0.4%$63.00+218.3%-44.7%$1.26BN/A-5.5340News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCRSPCRISPR Therapeutics3.6722 of 5 stars$59.59+6.2%$70.07+17.6%+18.4%$5.15B$37.31M-13.18460Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionLNTHLantheus4.6142 of 5 stars$71.46+1.3%$131.20+83.6%-42.9%$4.94B$1.53B20.30700Trending NewsEarnings ReportAnalyst ForecastADMAADMA Biologics4.2927 of 5 stars$19.91+3.0%$27.67+39.0%+46.3%$4.75B$426.45M23.42530Earnings ReportAnalyst RevisionMRUSMerus3.046 of 5 stars$66.93+2.1%$86.40+29.1%+29.4%$4.63B$36.13M-16.4037Earnings ReportAnalyst ForecastAnalyst RevisionABVXAbivax3.4744 of 5 stars$72.07+0.2%$92.33+28.1%+521.8%$4.57BN/A0.0061Upcoming EarningsTGTXTG Therapeutics4.0027 of 5 stars$28.72-18.0%$43.80+52.5%+39.5%$4.56B$386.39M119.67290Trending NewsEarnings ReportAnalyst RevisionHigh Trading VolumeTLXTelix PharmaceuticalsN/A$13.32+2.1%$22.33+67.7%N/A$4.51B$783.21M0.00N/ARNAAvidity Biosciences2.6024 of 5 stars$37.34+4.0%$66.35+77.7%+15.6%$4.50B$10.90M-12.45190News CoverageAnalyst ForecastCYTKCytokinetics4.1137 of 5 stars$36.58-0.3%$70.92+93.9%-31.2%$4.37B$19.22M-6.91250News CoverageEarnings ReportPCVXVaxcyte1.9025 of 5 stars$33.72+2.1%$136.50+304.8%-57.4%$4.35BN/A-8.45160News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies CRISPR Therapeutics Competitors Lantheus Competitors ADMA Biologics Competitors Merus Competitors Abivax Competitors TG Therapeutics Competitors Telix Pharmaceuticals Competitors Avidity Biosciences Competitors Cytokinetics Competitors Vaxcyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
